Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GLP1R | P43220 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26724313 | 0.89 | CHRM3 (0.41) | CHRM3RAB9A | |
| SCHEMBL26999935 | 0.86 | CHRM3 (0.44) | CHRM3RAB9AGLP1RCHRNB2CHRNA5 | |
| SCHEMBL26999934 | 0.83 | CHRNB2 (0.47) | CHRM3CHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL26724374 | 0.80 | CHRM3 (0.42) | CHRM3RAB9ACHRNB2CHRNA5CHRNA7 | |
| SCHEMBL26208635 | 0.80 | CHRM3 (0.46) | CHRM3RAB9AGLP1RCHRNB2CHRNA5 | |
| SCHEMBL21555134 | 0.79 | CHRM3 (0.39) | CHRM3RAB9A | |
| SCHEMBL26724267 | 0.77 | CHRM3 (0.42) | CHRM3CHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL26724256 | 0.77 | CHRM3 (0.42) | CHRM3CHRNB2CHRNA5CHRNA7CHRNA4 | |
| SCHEMBL26208260 | 0.77 | CHRM3 (0.45) | CHRM3RAB9AGLP1RCHRNB2CHRNA5 | |
| SCHEMBL26999903 | 0.77 | CHRM3 (0.45) | CHRM3RAB9AGLP1RCHRNB2CHRNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2023-11-09 | — | — | US | disclosed |
| WO-2023168367-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357158-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | CHRM3 179/4885RAB9A 2346/4885GLP1R 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.